[Form 4] Astera Labs, Inc. Insider Trading Activity
Astera Labs CFO Michael Truett Tate reported multiple stock sales on 08/12/2025. The Form 4 shows dispositions of 66,561, 32,374 and 1,065 shares of common stock sold at weighted-average prices of approximately $190.8154, $191.9162 and $192.5156, respectively, and an additional 278,373 shares disposed, for a combined total of 378,373 shares sold on that date. Following the reported transactions, the filing lists beneficial ownership totals of 434,935, 402,561 and 401,496 shares in related entries, with indirect ownership noted by the Tate 1997 Living Trust and by GlobalStar DAF. The filing includes weighted price ranges for each sale series and a signature by an attorney-in-fact dated 08/14/2025. The reporting person disclaims beneficial ownership of trust- and DAF-held shares except for any pecuniary interest.
Il CFO di Astera Labs, Michael Truett Tate, ha segnalato pi霉 vendite di azioni il 12/08/2025. Il Modulo 4 indica cessioni di 66.561, 32.374 e 1.065 azioni ordinarie, vendute a prezzi medi ponderati di circa $190,8154, $191,9162 e $192,5156, rispettivamente, e un'ulteriore cessione di 278.373 azioni, per un totale complessivo di 378.373 azioni vendute in quella data. A seguito delle operazioni riportate, la dichiarazione riporta totale di titolarit脿 beneficiaria pari a 434.935, 402.561 e 401.496 azioni nelle voci correlate, con la titolarit脿 indiretta indicata dal Tate 1997 Living Trust e da GlobalStar DAF. Il documento include gli intervalli di prezzo ponderati per ciascuna serie di vendite e una firma di un procuratore datata 14/08/2025. La persona che effettua la segnalazione dichiara di non rivendicare la titolarit脿 beneficiaria delle azioni detenute dal trust e dal DAF, salvo qualsiasi interesse pecuniario.
El CFO de Astera Labs, Michael Truett Tate, inform贸 varias ventas de acciones el 12/08/2025. El Formulario 4 muestra disposiciones de 66.561, 32.374 y 1.065 acciones ordinarias vendidas a precios ponderados promedio de aproximadamente $190,8154, $191,9162 y $192,5156, respectivamente, y una disposici贸n adicional de 278.373 acciones, para un total combinado de 378.373 acciones vendidas en esa fecha. Tras las transacciones informadas, la presentaci贸n enumera totales de propiedad beneficiosa de 434.935, 402.561 y 401.496 acciones en entradas relacionadas, con propiedad indirecta indicada por el Tate 1997 Living Trust y por GlobalStar DAF. La presentaci贸n incluye rangos de precios ponderados para cada serie de ventas y una firma de un apoderado fechada el 14/08/2025. La persona informante renuncia a la titularidad beneficiaria de las acciones mantenidas por el trust y el DAF, salvo cualquier inter茅s pecuniario.
Astera Labs鞚� CFO Michael Truett Tate臧� 2025-08-12鞐� 鞐煬 彀 欤检嫕 毵り皝鞚� 鞁犼碃頄堨姷雼堧嫟. 靹滌嫕 4鞐愲姅 氤错喌欤� 66,561, 32,374, 1,065欤缄皜 臧侁皝 臧�欷戫弶攴� 鞎� $190.8154, $191.9162, $192.5156鞐� 觳橂秳霅� 雮挫棴瓿� 於旉皜搿� 278,373欤缄皜 觳橂秳霅橃柎 頃措嫻 雮犾鞐� 齑� 378,373欤缄皜 毵る弰霅� 瓴冹溂搿� 雮橃櫠� 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 頉� 頃措嫻 鞝滌稖靹滊鞐愲姅 甏�霠� 頃鞐� 雽�頃� 434,935, 402,561, 401,496欤检潣 鞁れ鞝� 氤挫湢 頃╆硠臧� 旮办灛霅橃柎 鞛堨溂氅�, 臧勳爲 靻岇湢電� Tate 1997 Living Trust鞕赌 GlobalStar DAF鞐� 鞚橅暣 氤挫湢霅� 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 臧� 毵る弰 鞁滊Μ歃堨潣 臧�欷� 臧�瓴� 氩旍渼鞕赌 2025-08-14鞛� 雽�毽澑鞚� 靹滊獏鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 鞁犿儊 氚� DAF臧� 氤挫湢頃� 欤检嫕鞐� 雽�頃� 旮堨爠鞝� 鞚挫澋鞚� 鞝滌櫢頃橁碃電� 鞁れ鞝� 氤挫湢毳� 欤检灔頃橃 鞎婋姅雼り碃 氚濏瀳瓿� 鞛堨姷雼堧嫟.
Le directeur financier d'Astera Labs, Michael Truett Tate, a d茅clar茅 plusieurs ventes d'actions le 12/08/2025. Le formulaire 4 indique des cessions de 66 561, 32 374 et 1 065 actions ordinaires vendues 脿 des prix moyens pond茅r茅s d'environ $190,8154, $191,9162 et $192,5156, respectivement, et une cession suppl茅mentaire de 278 373 actions, pour un total combin茅 de 378 373 actions vendues 脿 cette date. 脌 la suite des transactions d茅clar茅es, le d茅p么t indique des totaux de propri茅t茅 b茅n茅ficiaire de 434 935, 402 561 et 401 496 actions dans les entr茅es correspondantes, la propri茅t茅 indirecte 茅tant not茅e par le Tate 1997 Living Trust et par GlobalStar DAF. Le d茅p么t inclut les fourchettes de prix pond茅r茅s pour chaque s茅rie de ventes et une signature d'un mandataire dat茅e du 14/08/2025. La personne d茅clarante d茅cline la propri茅t茅 b茅n茅ficiaire des actions d茅tenues par le trust et le DAF, sauf en ce qui concerne tout int茅r锚t p茅cuniaire.
Astera Labs CFO Michael Truett Tate meldete mehrere Aktienverk盲ufe am 12.08.2025. Das Formular 4 zeigt Ver盲u脽erungen von 66.561, 32.374 und 1.065 Stammaktien, verkauft zu gewichteten Durchschnittspreisen von etwa $190,8154, $191,9162 und $192,5156, sowie eine zus盲tzliche Ver盲u脽erung von 278.373 Aktien, womit sich an diesem Datum eine Gesamtsumme von 378.373 verkauften Aktien ergibt. Nach den gemeldeten Transaktionen f眉hrt die Einreichung vorteilhafte gehaltene Best盲nde von 434.935, 402.561 und 401.496 Aktien in den zugeh枚rigen Eintr盲gen auf, wobei indirekter Besitz durch den Tate 1997 Living Trust und GlobalStar DAF vermerkt ist. Die Einreichung enth盲lt die gewichteten Preisbereiche f眉r jede Verkaufsserie sowie die Unterschrift eines Bevollm盲chtigten datiert 14.08.2025. Die meldende Person lehnt den Anspruch auf vorteilhafte Eigent眉merschaft der vom Trust und DAF gehaltenen Aktien ab, mit Ausnahme eines etwaigen pecuni盲ren Interesses.
- Timely, detailed disclosure of multiple sales including weighted-average price ranges
- Clear identification of indirect ownership via the Tate 1997 Living Trust and GlobalStar DAF with standard disclaimers
- Large insider dispositions totaling 378,373 shares on 08/12/2025, which may be material to some investors
- No explanatory context in the filing about the reason for the sales (e.g., 10b5-1 plan or liquidity needs)
Insights
TL;DR: Significant insider selling disclosed; sale prices clustered near $191, no additional context provided.
The Form 4 documents sizable dispositions by the company's CFO totaling 378,373 shares on 08/12/2025 at weighted average prices around $190.50鈥�$192.55. The filing supplies precise weighted-average price ranges and post-transaction beneficial ownership figures, which supports transparent reporting. There is no commentary in the filing about the purpose of the sales or any corresponding purchases, so the transactions should be interpreted as reported events without further context. For valuation impact, investors would compare the sale volume to outstanding shares and recent trading volume outside this form.
TL;DR: Filing meets disclosure requirements; trustee-held shares and disclaimers are clearly stated.
The Form 4 correctly identifies the reporting person as an officer (CFO) and notes indirect ownership through the Tate 1997 Living Trust and the GlobalStar DAF with the customary disclaimer of beneficial ownership. Multiple price-range footnotes provide granular execution detail, and the form is signed by an attorney-in-fact. The filing does not allege any related-party transactions or plans (e.g., 10b5-1), so from a governance perspective the document fulfills Section 16 reporting obligations but does not explain the economic or corporate rationale for the dispositions.
Il CFO di Astera Labs, Michael Truett Tate, ha segnalato pi霉 vendite di azioni il 12/08/2025. Il Modulo 4 indica cessioni di 66.561, 32.374 e 1.065 azioni ordinarie, vendute a prezzi medi ponderati di circa $190,8154, $191,9162 e $192,5156, rispettivamente, e un'ulteriore cessione di 278.373 azioni, per un totale complessivo di 378.373 azioni vendute in quella data. A seguito delle operazioni riportate, la dichiarazione riporta totale di titolarit脿 beneficiaria pari a 434.935, 402.561 e 401.496 azioni nelle voci correlate, con la titolarit脿 indiretta indicata dal Tate 1997 Living Trust e da GlobalStar DAF. Il documento include gli intervalli di prezzo ponderati per ciascuna serie di vendite e una firma di un procuratore datata 14/08/2025. La persona che effettua la segnalazione dichiara di non rivendicare la titolarit脿 beneficiaria delle azioni detenute dal trust e dal DAF, salvo qualsiasi interesse pecuniario.
El CFO de Astera Labs, Michael Truett Tate, inform贸 varias ventas de acciones el 12/08/2025. El Formulario 4 muestra disposiciones de 66.561, 32.374 y 1.065 acciones ordinarias vendidas a precios ponderados promedio de aproximadamente $190,8154, $191,9162 y $192,5156, respectivamente, y una disposici贸n adicional de 278.373 acciones, para un total combinado de 378.373 acciones vendidas en esa fecha. Tras las transacciones informadas, la presentaci贸n enumera totales de propiedad beneficiosa de 434.935, 402.561 y 401.496 acciones en entradas relacionadas, con propiedad indirecta indicada por el Tate 1997 Living Trust y por GlobalStar DAF. La presentaci贸n incluye rangos de precios ponderados para cada serie de ventas y una firma de un apoderado fechada el 14/08/2025. La persona informante renuncia a la titularidad beneficiaria de las acciones mantenidas por el trust y el DAF, salvo cualquier inter茅s pecuniario.
Astera Labs鞚� CFO Michael Truett Tate臧� 2025-08-12鞐� 鞐煬 彀 欤检嫕 毵り皝鞚� 鞁犼碃頄堨姷雼堧嫟. 靹滌嫕 4鞐愲姅 氤错喌欤� 66,561, 32,374, 1,065欤缄皜 臧侁皝 臧�欷戫弶攴� 鞎� $190.8154, $191.9162, $192.5156鞐� 觳橂秳霅� 雮挫棴瓿� 於旉皜搿� 278,373欤缄皜 觳橂秳霅橃柎 頃措嫻 雮犾鞐� 齑� 378,373欤缄皜 毵る弰霅� 瓴冹溂搿� 雮橃櫠� 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 頉� 頃措嫻 鞝滌稖靹滊鞐愲姅 甏�霠� 頃鞐� 雽�頃� 434,935, 402,561, 401,496欤检潣 鞁れ鞝� 氤挫湢 頃╆硠臧� 旮办灛霅橃柎 鞛堨溂氅�, 臧勳爲 靻岇湢電� Tate 1997 Living Trust鞕赌 GlobalStar DAF鞐� 鞚橅暣 氤挫湢霅� 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 臧� 毵る弰 鞁滊Μ歃堨潣 臧�欷� 臧�瓴� 氩旍渼鞕赌 2025-08-14鞛� 雽�毽澑鞚� 靹滊獏鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 鞁犿儊 氚� DAF臧� 氤挫湢頃� 欤检嫕鞐� 雽�頃� 旮堨爠鞝� 鞚挫澋鞚� 鞝滌櫢頃橁碃電� 鞁れ鞝� 氤挫湢毳� 欤检灔頃橃 鞎婋姅雼り碃 氚濏瀳瓿� 鞛堨姷雼堧嫟.
Le directeur financier d'Astera Labs, Michael Truett Tate, a d茅clar茅 plusieurs ventes d'actions le 12/08/2025. Le formulaire 4 indique des cessions de 66 561, 32 374 et 1 065 actions ordinaires vendues 脿 des prix moyens pond茅r茅s d'environ $190,8154, $191,9162 et $192,5156, respectivement, et une cession suppl茅mentaire de 278 373 actions, pour un total combin茅 de 378 373 actions vendues 脿 cette date. 脌 la suite des transactions d茅clar茅es, le d茅p么t indique des totaux de propri茅t茅 b茅n茅ficiaire de 434 935, 402 561 et 401 496 actions dans les entr茅es correspondantes, la propri茅t茅 indirecte 茅tant not茅e par le Tate 1997 Living Trust et par GlobalStar DAF. Le d茅p么t inclut les fourchettes de prix pond茅r茅s pour chaque s茅rie de ventes et une signature d'un mandataire dat茅e du 14/08/2025. La personne d茅clarante d茅cline la propri茅t茅 b茅n茅ficiaire des actions d茅tenues par le trust et le DAF, sauf en ce qui concerne tout int茅r锚t p茅cuniaire.
Astera Labs CFO Michael Truett Tate meldete mehrere Aktienverk盲ufe am 12.08.2025. Das Formular 4 zeigt Ver盲u脽erungen von 66.561, 32.374 und 1.065 Stammaktien, verkauft zu gewichteten Durchschnittspreisen von etwa $190,8154, $191,9162 und $192,5156, sowie eine zus盲tzliche Ver盲u脽erung von 278.373 Aktien, womit sich an diesem Datum eine Gesamtsumme von 378.373 verkauften Aktien ergibt. Nach den gemeldeten Transaktionen f眉hrt die Einreichung vorteilhafte gehaltene Best盲nde von 434.935, 402.561 und 401.496 Aktien in den zugeh枚rigen Eintr盲gen auf, wobei indirekter Besitz durch den Tate 1997 Living Trust und GlobalStar DAF vermerkt ist. Die Einreichung enth盲lt die gewichteten Preisbereiche f眉r jede Verkaufsserie sowie die Unterschrift eines Bevollm盲chtigten datiert 14.08.2025. Die meldende Person lehnt den Anspruch auf vorteilhafte Eigent眉merschaft der vom Trust und DAF gehaltenen Aktien ab, mit Ausnahme eines etwaigen pecuni盲ren Interesses.
FAQ
What did Astera Labs (ALAB) CFO Michael T. Tate sell on 08/12/2025?
At what prices were the ALAB shares sold in the Form 4?
Does the Form 4 indicate indirect ownership for Michael Tate?
When was the Form 4 signed and filed?
Does the filing state the sales were made under a 10b5-1 plan?
